|Assessment Status||Rapid Review complete|
|Indication||Treatment of hyperammonaemia due to N-acetyl-glutamate synthase (NAGS) primary deficiency.|
|Rapid review commissioned||16/05/2022|
|Rapid review completed||21/06/2022|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that carglumic acid (Ucedane®) not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.